Universal Flu Opportunity Target health systems, contract manufacturers, and veterinary networks with EnGen Bio's universal Type A flu vaccines and potential therapeutic antibodies, emphasizing both human and animal health markets and the significant global flu burden.

Early-Stage Partnership Position EnGen Bio as a high-impact early-stage biotech partner for funding, strategic collaborations, and co-development agreements via targeted outreach to biotech investors, advocacy groups, and crowdfunding platforms to accelerate clinical timelines.

Crowdfunding traction Leverage past and planned fundraising activities with WeFunder to attract non-traditional biotech investors and patient/advocacy networks, creating a channel for pre-seed and seed rounds and validating market interest.

Global market potential Quantify and package the combined $6B human, $0.5B veterinary, and additional $2B therapeutic market potential to tailor value propositions for pharmaceutical manufacturers, distributors, and large animal health players seeking broad-spectrum influenza solutions.

Operational readiness Highlight the small team and existing tech stack as a narrative for outsourced manufacturing and rapid deployment partnerships, offering white-label or contracted development models to overcome early-stage capacity constraints.